THOUSAND OAKS, Calif., Oct. 30, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2024.

Discover five T cell engager companies that have emerged in recent times, as this class of therapeutics is set to take off.

Amgen AMGN reported third-quarter 2024 adjusted earnings of ... Lumakras/Lumykras recorded sales of $98 million in the quarter, up 88% from the year-ago period. Imdelltra (tarlatamab), approved for ...

(RTTNews) - Amgen Inc. (AMGN) reported earnings for its third quarter that increased from the same period last year and beat the Street estimates. The company's bottom line came in at $2.83 ...

* The known adjustments are presented net of their related tax impact, which amount to approximately $2.39 per share. (a) The adjustments primarily include noncash amortization of intangible ...

* The known adjustments are presented net of their related tax impact, which amount to approximately $2.39 per share. (a) The adjustments primarily include noncash amortization of intangible assets ...

THOUSAND OAKS, Calif., Oct. 30, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2024. "Strong growth in sales and earnings this quarter reflects ...

Early successes from Paul G. Allen Research Center team members include: Its first clinical trial opened in February 2023 to examine the role of Tarlatamab in lung cancer as part of a multicenter ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...